Lasa Supergenerics Limited
NSE: LASA BSE: LASA
Prev Close
10.19
Open Price
10.09
Volume
28,849
Today Low / High
9.85 / 10.49
52 WK Low / High
8.42 / 33.49
Range
10 - 11
Prev Close
10.45
Open Price
10.45
Volume
17,103
Today Low / High
9.93 / 10.66
52 WK Low / High
8.52 / 33.49
Range
10 - 11
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 10.2 (target range: 10 - 11), reflecting a change of 0.01 (0.09813543%). On the BSE, it is listed at 10.21 (target range: 10 - 11), showing a change of -0.24 (-2.29665%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Lasa Supergenerics Limited Graph
Lasa Supergenerics Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lasa Supergenerics Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 10.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 10.21 | 10.31 | 9.28 - 11.34 |
10.41 | 8.33 - 12.50 | ||
10.52 | 7.36 - 13.67 | ||
Bearish Scenario | 10.21 | 10.11 | 9.10 - 11.12 |
10.01 | 8.00 - 12.01 | ||
9.90 | 6.93 - 12.87 |
Overview of Lasa Supergenerics Limited
ISIN
INE670X01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
164,572
Market Cap
513,537,300
Last Dividend
0
Official Website
IPO Date
2017-09-21
DCF Diff
4.11
DCF
6
Financial Ratios Every Investor Needs
Stock Dividend of LASA
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2022-09-16 | September 16, 22 | 0.25 | 0.25 | 2022-09-19 | 2022-10-26 | |
2021-09-15 | September 15, 21 | 0.25 | 0.25 | 2021-09-16 | 2021-10-24 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 142.45 Cr | 106.19 Cr | 36.26 Cr | 0.2546 | 0.00 Cr | 0.00 Cr | -6.03 Cr | -14.76 Cr | -2.95 | -4.39 Cr | -0.1036 |
2024-03-31 | 104.34 Cr | 75.64 Cr | 28.70 Cr | 0.2750 | 0.13 Cr | 3.22 Cr | -8.43 Cr | -21.73 Cr | -4.34 | -6.51 Cr | -0.2083 |
2023-03-31 | 129.57 Cr | 140.76 Cr | -11.19 Cr | -0.0863 | 0.10 Cr | 3.57 Cr | -18.10 Cr | -38.62 Cr | -7.71 | -24.69 Cr | -0.2981 |
2022-03-31 | 137.13 Cr | 94.34 Cr | 42.78 Cr | 0.3120 | 0.20 Cr | 5.10 Cr | 2.33 Cr | -5.33 Cr | -1.06 | 8.41 Cr | -0.0389 |
2021-03-31 | 202.38 Cr | 113.69 Cr | 88.69 Cr | 0.4382 | 0.37 Cr | 4.00 Cr | 31.44 Cr | 22.78 Cr | 5.60 | 46.99 Cr | 0.1125 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 0.28 Cr | 101.53 Cr | 17.82 Cr | 83.7133 Cr | 2.13 Cr | 1.85 Cr | 24.50 Cr | 48.34 Cr | 0.00 Cr | 0.00 Cr | 0.78 Cr | 17.1545 Cr |
2024-03-31 | 0.61 Cr | 150.87 Cr | 54.19 Cr | 96.6762 Cr | 22.08 Cr | 21.47 Cr | 19.04 Cr | 86.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 48.8705 Cr |
2023-03-31 | 0.80 Cr | 163.86 Cr | 45.57 Cr | 118.2860 Cr | 21.77 Cr | 20.97 Cr | 13.90 Cr | 92.78 Cr | 0.00 Cr | 0.00 Cr | 0.39 Cr | 42.7279 Cr |
2022-03-31 | 11.07 Cr | 209.17 Cr | 51.29 Cr | 157.8829 Cr | 20.17 Cr | 9.11 Cr | 11.50 Cr | 125.09 Cr | 0.18 Cr | 0.00 Cr | 0.38 Cr | 44.7497 Cr |
2021-03-31 | 3.84 Cr | 207.86 Cr | 48.94 Cr | 158.9171 Cr | 19.46 Cr | 15.62 Cr | 17.26 Cr | 137.51 Cr | 0.04 Cr | 0.00 Cr | 0.02 Cr | 40.5354 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | -2.8237 Cr | 8.1520 Cr | -5.6616 Cr | -2.8237 Cr | -0.3333 Cr | 0.2753 Cr | 0.0000 Cr | -19.3831 Cr | -5.2526 Cr | 0.0000 Cr | -5.4537 Cr |
2024-03-31 | 2.1387 Cr | -0.3978 Cr | -1.9319 Cr | 2.1387 Cr | -0.1909 Cr | 0.6086 Cr | 0.0000 Cr | -21.7306 Cr | 0.0000 Cr | 0.0000 Cr | -5.1404 Cr |
2023-03-31 | -17.3004 Cr | 11.1949 Cr | -4.1606 Cr | -17.3004 Cr | -10.2661 Cr | 0.7995 Cr | 0.0000 Cr | -22.3685 Cr | 0.0000 Cr | 0.0000 Cr | -2.4053 Cr |
2022-03-31 | 9.2116 Cr | -2.9119 Cr | -0.0403 Cr | 9.2116 Cr | 6.2594 Cr | 11.0656 Cr | 0.0000 Cr | 1.6506 Cr | 0.0000 Cr | 0.0000 Cr | 5.7609 Cr |
2021-03-31 | 41.3103 Cr | -3.5967 Cr | -36.4433 Cr | 34.7237 Cr | 1.2703 Cr | 3.8387 Cr | -6.5866 Cr | 29.4914 Cr | -34.4802 Cr | 0.0000 Cr | 9.0462 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 39.14 Cr | 28.33 Cr | 10.81 Cr | 0.2763 | -1.01 Cr | -14.29 Cr | -2.86 | -7.77 Cr | -0.3652 |
2024-12-31 | 33.08 Cr | 24.51 Cr | 8.57 Cr | 0.2589 | -2.01 Cr | 5.49 Cr | 1.10 | 0.79 Cr | 0.1661 |
2024-09-30 | 39.39 Cr | 31.28 Cr | 8.12 Cr | 0.2060 | -2.02 Cr | -3.23 Cr | -0.64 | 2.74 Cr | -0.0820 |
2024-06-30 | 30.84 Cr | 26.48 Cr | 4.36 Cr | 0.1413 | -1.00 Cr | -2.73 Cr | -0.55 | 1.80 Cr | -0.0886 |
2024-03-31 | 22.82 Cr | 22.65 Cr | 0.17 Cr | 0.0075 | -6.57 Cr | -15.30 Cr | -3.05 | -12.75 Cr | -0.6706 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 0.28 Cr | 0.52 Cr | 0.79 Cr | 1.54 Cr | 24.50 Cr | 32.51 Cr | 48.34 Cr | 101.53 Cr | 17.82 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 1.13 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -90.72 Cr |
2024-09-30 | 0.73 Cr | 0.40 Cr | 1.13 Cr | 3.74 Cr | 20.24 Cr | 39.33 Cr | 83.73 Cr | 147.33 Cr | 56.61 Cr |
2024-06-30 | 0.00 Cr | 0.00 Cr | 1.50 Cr | 0.00 Cr | 0.00 Cr | 1.50 Cr | 0.00 Cr | 0.00 Cr | -96.68 Cr |
2024-03-31 | 0.61 Cr | 0.89 Cr | 1.50 Cr | 3.58 Cr | 19.04 Cr | 37.89 Cr | 86.33 Cr | 150.87 Cr | 54.19 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 5.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | -3.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | -2.73 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | -15.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | -1.46 Cr | 5.36 Cr | 0.00 Cr | 0.00 Cr | 5.36 Cr | 7.13 Cr | 1.77 Cr | 0.00 Cr | 5.36 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,640.90 | ₹3,936,978,552,000.00 | ₹1,313,620.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,100.50 | ₹1,619,493,634,500.00 | ₹394,932.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,617.80 | ₹1,224,426,321,000.00 | ₹287,405.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,253.40 | ₹1,043,245,022,805.00 | ₹1,191,889.00 |
Mankind Pharma Limited | MANKIND | ₹2,466.00 | ₹1,017,789,122,160.00 | ₹376,033.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.60 | ₹994,758,978,000.00 | ₹1,911,246.00 |
Lupin Limited | LUPIN | ₹1,989.80 | ₹908,835,180,600.00 | ₹875,748.00 |
Alkem Laboratories Limited | ALKEM | ₹5,388.50 | ₹644,276,002,500.00 | ₹899,623.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,078.20 | ₹626,220,716,400.00 | ₹444,368.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,029.30 | ₹572,670,489,300.00 | ₹466,363.00 |
Laurus Labs Limited | LAURUSLABS | ₹863.15 | ₹465,949,948,750.00 | ₹2,817,579.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Cohance Lifesciences Limited | COHANCE | ₹986.05 | ₹377,230,198,238.00 | ₹177,879.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,364.60 | ₹346,204,478,400.00 | ₹113,365.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,671.70 | ₹333,791,511,200.00 | ₹40,260.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,715.50 | ₹268,163,529,000.00 | ₹62,276.00 |
Piramal Enterprises Limited | PEL | ₹1,127.20 | ₹255,511,441,600.00 | ₹243,681.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,501.60 | ₹243,978,466,400.00 | ₹325,967.00 |
Eris Lifesciences Limited | ERIS | ₹1,674.80 | ₹228,119,483,600.00 | ₹42,022.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,416.50 | ₹210,412,500,000.00 | ₹34,705.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹941.00 | ₹184,965,783,000.00 | ₹25,900.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,077.50 | ₹171,625,277,500.00 | ₹132,577.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹13,018.00 | ₹167,019,638,200.00 | ₹23,483.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,156.90 | ₹163,949,635,730.00 | ₹164,102.00 |
NATCO Pharma Limited | NATCOPHARM | ₹904.25 | ₹161,960,217,500.00 | ₹516,819.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹460.35 | ₹111,701,165,400.00 | ₹778,530.00 |
Procter & Gamble Health Limited | PGHL | ₹6,182.50 | ₹102,625,790,500.00 | ₹13,202.00 |
Shilpa Medicare Limited | SHILPAMED | ₹906.20 | ₹88,618,113,580.00 | ₹114,891.00 |
Strides Pharma Science Limited | STAR | ₹867.30 | ₹79,941,382,710.00 | ₹568,013.00 |
FDC Limited | FDC | ₹483.20 | ₹78,669,792,000.00 | ₹76,497.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹790.45 | ₹71,642,135,379.00 | ₹1,229,147.00 |
Innova Captab Limited | INNOVACAP | ₹902.00 | ₹51,616,886,860.00 | ₹24,559.00 |
Suven Life Sciences Limited | SUVEN | ₹232.25 | ₹50,647,686,500.00 | ₹235,893.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹142.28 | ₹46,172,990,160.00 | ₹192,243.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹488.05 | ₹44,544,323,500.00 | ₹79,719.00 |
Sequent Scientific Limited | SEQUENT | ₹171.51 | ₹42,934,955,850.00 | ₹221,470.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹768.10 | ₹38,957,340,710.00 | ₹102,241.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,281.60 | ₹37,735,382,400.00 | ₹9,674.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹513.80 | ₹36,174,500,040.00 | ₹45,592.00 |
Gufic Biosciences Limited | GUFICBIO | ₹356.70 | ₹35,769,162,600.00 | ₹36,115.00 |
Hikal Limited | HIKAL | ₹255.65 | ₹31,521,900,650.00 | ₹589,191.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹605.30 | ₹29,147,010,900.00 | ₹54,573.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹93.23 | ₹27,365,522,210.00 | ₹1,598,864.00 |
Indoco Remedies Limited | INDOCO | ₹293.70 | ₹27,093,208,230.00 | ₹138,144.00 |
Alembic Limited | ALEMBICLTD | ₹105.19 | ₹27,010,898,475.00 | ₹451,825.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹47.31 | ₹25,923,703,740.00 | ₹3,167,804.00 |
Key Executives
Gender: male
Year Born: 1984
Gender: Not Specified
Year Born: 1981
Gender: female
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Lasa Supergenerics Limited
The CEO is Omkar Pravin Herlekar.
The current price is ₹10.25.
The range is ₹8.42-33.49.
The market capitalization is ₹51.35 crores.
The P/E ratio is -3.47.
The company operates in the Healthcare sector.
Overview of Lasa Supergenerics Limited (ISIN: INE670X01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹51.35 crores and an average daily volume of 164,572 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.